Researchers have discovered a first-of-its-kind blood test for Alzheimer’s disease that can predict – with 90 percent accuracy – if a healthy person will develop this cruel disease within three years.
Dr. Howard Federoff, the Executive Vice President for Health Sciences and Executive Dean of Georgetown University School of Medicine, led the team and will brief us in our next Alzheimer’s Talks conversation on May 16 on why his biomarker study is a potential game-changer.
The possibility of catching the disease before a patient ever shows symptoms brings us even closer to finding effective means of prevention. A blood test will enable us to identify people who will get Alzheimer’s disease and give them a drug to prevent symptoms. That’s why Dr. Federoff’s work is so essential to moving toward our goal to end Alzheimer’s by 2020.